(Earlier today, December 11, 2019, a press release was incorrectly published citing the Market Abuse Regulation (MAR). The information in the press release is regulatory but not of a MAR nature).
Jessica Roxhed joins Dicot as CFO, Julie Silber's role as Director of Investor Relations expands and Gabriela Urquilla will head up external communications, reporting to the Director of IR, effective December 15, 2019.
December 11, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") today announced that the company has expanded its management team with the addition of Jessica Roxhed as its new CFO, effective December 15, 2019. In this role, Jessica will be responsible for leading financial activities, including overseeing accounting, internal audit, budgets and annual and interim reporting. Julie Silber will continue in the expanded role as Director of Investor Relations and Gabriela Urquilla will join the Investor Relations team to project manage and help coordinate Dicot's expanded communications efforts. Gabriela will work closely with Julie Silber in the development and creation of content/materials for Dicot's strategic communications endeavors as well as help Julie coordinate investor roadshows, targeting institutional investor conferences and providing logistics support, as Dicot continues to foster and maintain long-term relationships with investors, shareholders, companies, and potential partners.
"I am pleased to announce the expansion of the Dicot team and to welcome Jessica to Dicot, as CFO. Jessica has a proven track record of strong financial leadership and I am confident that her insights and experience will be very valuable as we simplify our company structure and create a more dynamic, agile organization," said Göran Beijer, CEO. "With Jessica, as CFO, Julie, as Director of Investor Relations and Gabriela as Director of Communications, we now have a skill set that will support Dicot's financial and IR efforts in its near and long-term strategic goals. We look forward to capitalizing on our future opportunities and delivering enhanced value to our shareholders."
Jessica brings over 15 years of corporate finance experience to Dicot AB, including Chief Financial Officer with broad experience in business administration and holding any other senior management positions in companies in various industries. Prior to joining Dicot, Jessica was the CFO of Senzime AB. Prior to that, Jessica served as the Controller for many companies, including Svenska kyrkan nationell nivå, Spoon Publishing AB, Vattenfall Service Nordic AB. She received her Master of Science in Business administration from the University of Uppsala.
Julie brings over 20 years of financial communications experience including executive financial leadership roles with both private and publicly held companies, several years as a for-hire equity analyst and over 10+ years as an IRO with several notable US based firms. Since moving to Sweden, Julie has specialized in gaining visibility and positioning smaller, Life Science companies to the local and global financial markets. She holds a bachelor"s degree in International Relations from the University of Southern California, a certificate in Accounting from the Center for Non-Profit Management and a master's degree in Environmental Science & Policy, also from USC.
Gabriela brings over 4 years of Pre-IPO, and public company investor relations experience coming from Wall Street, and now Stockholm, where she developed her expertise within the technology, medical technology, diagnostics, life science, specialty pharma, and medical aesthetic sectors. Prior to joining Dicot, she was an analyst at The Ruth Group in New York City, specializing in Life Sciences. Gabriela received her Bachelor of Arts in communication and business from Wesleyan College.
For further information, please contact:
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients" lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company"s lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 860 shareholders. For more information see www.dicot.se.